Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BETP 是胰高血糖素样肽 (GLP-1) 受体激动剂,能够抑制人和大鼠的GLP-1受体,其EC50值分别为 0.66 μM 和 0.755 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 346 | 现货 | ||
2 mg | ¥ 513 | 现货 | ||
5 mg | ¥ 888 | 现货 | ||
10 mg | ¥ 1,370 | 现货 | ||
25 mg | ¥ 2,680 | 现货 | ||
50 mg | ¥ 3,920 | 现货 | ||
100 mg | ¥ 5,690 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 978 | 现货 |
产品描述 | BETP is an agonist of GLP-1 receptor (EC50s: 0.66 and 0.755 μM for human and rat GLP-1 receptor). |
靶点活性 | GLP1:0.66 μM(Human), GLP1:0.755 μM(Rat) |
体外活性 | BETP(化合物B)在表达GLP-2、GIP、PTH或胰高血糖素受体的细胞中无活性。BETP(1-10 μM)能增强正常和糖尿病患者胰岛的胰岛素分泌。此外,BETP与GLP-1联用时,对GLP-1受体信号的增强作用呈现加成效应[1]。BETP将羟硝苏肽的效力提高了10倍(EC50:80 pM)。GLP-1不会改变羟硝苏肽和胰高血糖素在胰高血糖素受体上的效力和效能。BETP(0-30 μM)提高了羟硝苏肽与GLP-1受体的结合亲和力[2]。 |
体内活性 | BETP(10 mg/kg,颈静脉导管)在静脉葡萄糖耐量试验(IVGTT)模型中显示出促进胰岛素分泌的活性。在SD大鼠高血糖夹持模型中,经BETP(10 mg/kg,静脉注射)处理的大鼠需要更高20%的葡萄糖输注率,并展现出更高的血浆胰岛素水平 [1]。此外,BETP(5 mg/kg)增强了oxyntomodulin刺激下的胰岛素分泌 [2]。 |
动物实验 | IVGTT studies are performed. Male SD rats are group-housed three per cage in polycarbonate cages with filter tops. Rats are maintained on a 12:12 h light-dark cycle (lights on at 6:00 a.m.) at 21°C and receive diet and deionized water ad libitum. Rats were fasted overnight and anesthetized with 60 mg/kg pentobarbital for the duration of the experiment. For glucose and compounds (BETP, etc.) administration, a catheter with a diameter of 0.84 mm is inserted into the jugular vein. For rapid blood collection, a larger catheter with 1.02-mm diameter is inserted into the carotid artery. Blood is collected for glucose and insulin levels at times 0, 2, 4, 6, 10, and 20 min after intravenous administration of the BETP which is immediately followed by an intravenous glucose bolus of 0.5 g/kg. Plasma levels of glucose and insulin are determined [1]. |
分子量 | 406.42 |
分子式 | C20H17F3N2O2S |
CAS No. | 1371569-69-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Insoluble
DMSO: 25 mg/mL (61.51 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4605 mL | 12.3025 mL | 24.6051 mL | 61.5127 mL |
5 mM | 0.4921 mL | 2.4605 mL | 4.921 mL | 12.3025 mL | |
10 mM | 0.2461 mL | 1.2303 mL | 2.4605 mL | 6.1513 mL | |
20 mM | 0.123 mL | 0.6151 mL | 1.2303 mL | 3.0756 mL | |
50 mM | 0.0492 mL | 0.2461 mL | 0.4921 mL | 1.2303 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BETP 1371569-69-5 GPCR/G Protein Glucagon Receptor inhibit GCGR Inhibitor inhibitor